Xadago (safinamide) was approved for the use of treatment in Parkinson’s disease as an add-on therapy with Sinemet (carbidopa-levodopa) by the U.S. Food and Drug Administration in early 2017 and became commercially available in July 2017.


 The drug’s mechanism of action is a monoamine oxidase (MAO)-B inhibitor that works by blocking the breakdown of levodopa in the brain, thus increasing its availability. The drug was designed to be used in patients already taking carbidopa-levodopa and who are experiencing “off” times. “Off” times are described as periods when Parkinson symptoms are worse including increased tremors, slowness of movement or stiffness.


The studies found that patients who used this medication in combination with carbidopa-levodopa experienced increased “on” time without bothersome dyskinesia. The drug is a once daily formula and starts at 50 mg for the first 2 weeks and is increased to 100 mg thereafter.

Contact the specialists at Central Neurology, P.L. for a consultation. They focus on a variety of neurological conditions, including treatment of Parkinson’s disease. 

Contributed by Heather A. Herrema, D.O.